At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 332 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab and Placebo for Ankylosing Spondylitis. Completed, enrolled 332 participants across 83 sites in 14 countries.
Detailed Summary
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesBelgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
First PostedApr 2019
Primary CompletionSep 2021
Study CompletionAug 2022
TodayJul 2026
First PostedApr 26, 2019
Enrollment StartApr 25, 2019
Primary CompletionSep 3, 2021
Study CompletionAug 8, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.2 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.
Placeboother
Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.